Cidara Therapeutics to Present New Data for Rezafungin at IDWeek 2022 SAN DIEGO, Oct. 17, 2022 (GLOBE NEWSWIRE) -- Cidara Therapeutics, Inc. (NASDAQ: CDTX), a biotechnology company developing long-acting therapeutics designed to improve the standard of care for patients facing serious diseases, today announced that it is presenting new clinical and preclinical data for rezafungin in six poster presentations at IDWeek taking place in-person in Washington, D.C. from October 19-23, 2022. The company will also participate in a pipeline symposium focused on new antimicrobials and ID diagnostics. Cidara retains the rights to rezafungin in Japan and has licensed the commercial rights to Melinta Therapeutics in the U.S. and Mundipharma Medical in all other geographies. Presenter: George R. Thompson III, M.D., UC Davis Session Title: Clinical trials
Date and Time: Thursday October 20, 2022, at 12:15 PM - 1:30 PM EDT
Title: Impact of Elevated MIC Values on Echinocandin Pharmacokinetic-Pharmacodynamic (PK-PD) Candida glabrata Target Attainment (TA) Presenter: Chris Rubino, Pharm.D., ICPD
Session Title: PK/PD studies
Date and Time: Thursday October 20, 2022, at 12:15 PM - 1:30 PM EDT
Lead Author: Tom Lodise, Pharm.D., Ph.D., Albany College of Pharmacy and Health Sciences Session Title: Medical Mycology
Date and Time: Thursday October 20, 2022, at 12:15 PM - 1:30 PM EDT
Presenter: Tom Lodise, Pharm.D., Ph.D., Albany College of Pharmacy and Health Sciences
Session Title: Medical Mycology
Date and Time: Thursday October 20, 2022, at 12:15 PM - 1:30 PM EDT
Presenter: Cecilia Carvalhaes, M.D., Ph.D., D(ABMM), JMI Laboratories Session Title: Antimicrobial Novel Agents
Date and Time: Saturday October 22, 2022, at 12:15 PM - 1:30 PM EDT
Presenter: Taylor Sandison, M.D., MPH, Cidara Session Title: Antimicrobial Novel Agents
Date and Time: Saturday October 22, 2022, at 12:15 PM - 1:30 PM EDT
Session Title: New Antimicrobials and ID Diagnostics in the Pipeline - Fungal
Presenter: Taylor Sandison, M.D., MPH, Cidara Date and Time: Saturday October 22, 2022, at 8:00 AM - 9:00 AM EDT
Cidara is developing long-acting therapeutics designed to improve the standard of care for patients facing serious diseases. The Company’s portfolio is comprised of new approaches aimed at transforming existing treatment and prevention paradigms, first with its lead Phase 3 antifungal candidate, rezafungin, in addition to drug-Fc conjugates (DFCs) targeting viral and oncology diseases from Cidara’s proprietary Cloudbreak® platform. Cidara is headquartered in San Diego, California. For more information, please visit www.cidara.com. Forward-Looking Statements
This release contains “forward-looking statements” within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended, and such forward-looking statements are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. “Forward-looking statements” describe future expectations, plans, results, or strategies and are generally preceded by words such as “anticipates,” “expect,” “may,” “plan” or “will”. Forward-looking statements in this release include, but are not limited to, statements related to our expectations regarding whether the FDA will approve the filed rezafungin NDA on or around the PDUFA target action date or at all, whether the ReSPECT trial for prophylaxis will be completed, and whether the ReSPECT data will be sufficient to support submission of a supplemental NDA application for the prophylaxis indication. Such statements are subject to a multitude of risks and uncertainties that could cause future circumstances, events, or results to differ materially from those projected in the forward-looking statements, such as unanticipated delays in or negative results from Cidara’s pre-clinical or clinical trials, delays in action by regulatory authorities due to limitations on inspections and other COVID-19-related effects, and impacts of the COVID-19 pandemic or other obstacles on the enrollment of patients or other aspects of rezafungin development. These and other risks are identified under the caption “Risk Factors” in Cidara’s most recent Quarterly Report on Form 10-Q and other filings subsequently made with the Securities and Exchange Commission. All forward-looking statements contained in this press release speak only as of the date on which they were made and are based on management’s assumptions and estimates as of such date. Cidara does not undertake any obligation to publicly update any forward-looking statements, whether as a result of the receipt of new information, the occurrence of future events or otherwise. britchie@lifesciadvisors.com